APPLICATION OF DESIGNED MPCR PRIMER FOR E6 GENE OF HPV TYPE 45 AND 52 IN CERVICAL CANCER PATIENTS
Abstract
Objective: Cervical cancer is the third disease that causes death in the world. The main cause of cervical cancer is Human papillomavirus (HPV). HPV have E6 and E7 oncogenes that, responsible for cancer incidence. One of molecular biology techniques for HPV identification is PCR. The aimed of this study is to applicate the multiplex PCR primer design for HPV type 45 and 52 identification.
Methods: DNA was isolated from 31 cervical cancer biopsy and cervical smear samples. DNA was amplicated with MY09/MY11 primer. Line probe array used to genotype of HPV. Application of primer design use MPCR methods with conditions was hot start 95 °C (3 min), denaturation 95 °C (15 s), annealing 58 °C (30 s), extension 72 °C (15 s) and final extension 72 °C (1 min). The amplified products were analyzed on a 1.5% agarose gel, stained with Gel Red and visualized in-gel documentation system.
Results: Result of HPV identification of HPV shown 19 of the 31 samples in this study was positive HPV. HPV genotyping was obtained the HPV type of the samples were HPV type 16, 18, 45 and 52. Application of design primer gives positive result. The band on S1, S2, S3 and S4 lane indicated the presence of gen E6 of HPV type 45 in J.1, J.3 and J.14 sample code and HPV type 52 in J.22 sample code.
Conclusion: MPCR primer design for E6 gene of HPV type 45 and 52 was applicated for identification of HPV type 45 and 52 in cervical cancer patients.
Keywords: Cervical cancer, Primer design, HPV type 45, HPV type 52, Multiplex PCR.
Downloads
References
Manuaba. Understanding the Female Reproductive Health. Jakarta: EGC; 2009.
Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Albero G, Cosano R, et al. Human papillomavirus and related diseases report in indonesia. barcelona: ICO information centre on HPV and cancer (HPV Information Centre); 2014. p. 33-40.
World Health Organization. Cervical cancer, human papillomavirus (HPV), and HPV vaccines-Key point for policy-makers and health professionals. Geneva, Switzerland: WHO Press; 2007.
Munoz S. Epidemiologic classification of human papillomavirus type in invasive servical cancer worldwide. N Engl J Med 2003;348:518-27.
Aldi Y, Trisnawati AN, Putra AE, Djamaan K, Marlina. Detection of hpv type 45 L2 gene in cervical cancer patients by polymerase chain reaction method. Int J Phram Pharm Sci 2015;7:129-32.
Motoyama S, Ladines-llave CA, Villanueva SL, Maruo T. The role of human papillomavirus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci 2004;50:9-19.
Ramadhani P, Marlina, Rustini, Aldi Y. Design primer for E6 Gen HPV Type 45 and 52 on cervical cancer patien use multiplex polimerase chain reaction (MPCR) method. National seminar and workshop Development Science Pharmacy and Clinical V†on Padang, Indonesia; 2015.
Molijn A, Berhard K, Wim Q, Leen JD. Molekular diagnosis of human papillomavirus (HPV) infection. J Clin Virol Elsevier 2005;32:34-51.
Weimin Q, Gang J, Yvette C, Chee JC, Gloria YF Ho, Robert SK, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP 5+/GP 6+Primer system. J Clin Microbiol 1997;35:1034-10.
Venceslau EM, Mauro MB, Anna CML, Érick VS, Alexandre SCO, Claudia MM, et al. HPV detection using primers MY09/MY11 and GP5+/GP6+in patients with cytologic and/or colposcopic changes. J Bras Patol Med Lab 2014;4:280-5.
Chang DY. Comparison of detection of human papillomavirus 16 DNA in cervical carcinoma tissues by southern blot hybridisation and nested polymerase chain reaction. J Med Microbiol 1995;43:430-5.
Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papilloma viruses. J Clin Microbiol 2000;38:357-61.